{
    "Rank": 699,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00774436",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "08-118"
                },
                "Organization": {
                    "OrgFullName": "Memorial Sloan Kettering Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Study of Focal Cryoablation in Low-Risk Prostate Cancer",
                "OfficialTitle": "A Phase II Study of Focal Cryoablation in Low-Risk Prostate Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "October 2018",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 14, 2008",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "July 23, 2019",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "July 23, 2019",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "October 15, 2008",
                "StudyFirstSubmitQCDate": "October 15, 2008",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "October 17, 2008",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "July 25, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "July 29, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Memorial Sloan Kettering Cancer Center",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {},
            "DescriptionModule": {
                "BriefSummary": "The purpose of this study is to find out if men, with low-risk prostate, can have the small amount of cancer within their prostate removed by freezing, called Focal Cryoablation or Cryotherapy."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Prostate Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "focal cryotherapy",
                        "low-risk prostate cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "12",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Patients scheduled to receive Focal Cryotherapy",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "After enrollment, patients will undergo a repeat transrectal ultrasound- guided prostate biopsy (minimum of 12 cores) to confirm the low-risk nature of their cancer. For study purposes, patients must meet the original entry crieteria on this repeat biopsy. If the patient meets the repeat-biopsy enrollment criteria, they will be treated with focal cryotherapy, meaning cryoablation of the regions of the prostate containing cancer. Efficacy is defined as all negative biopsy cores at the site of the focal ablation on a repeat transrectal biopsy 6 months after cryoablation. At baseline (prior to the re-staging biopsy), 3 months after focal cryotherapy, and at 6 months after focal cryotherapy (prior to the repeat prostate biopsy used to define efficacy), the patient will complete quality of life questionnaires as standard for all patients in the Urology Service.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Procedure: focal cryotherapy"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "focal cryotherapy",
                            "InterventionDescription": "Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Patients scheduled to receive Focal Cryotherapy"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "To assess the local oncologic efficacy of focal cryoablation in men with low-risk, clinically localized prostate cancer, as measured by the ability to obtain all negative biopsy cores at the site of focal ablation of the cancer.",
                            "PrimaryOutcomeTimeFrame": "conclusion of the study"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "To evaluate the change from baseline in quality-of-life indicators following focal cryoablation in patients with low-risk localized prostate cancer.",
                            "SecondaryOutcomeTimeFrame": "conclusion of the study"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To evaluate treatment related tissue changes with ultrasound imaging",
                            "SecondaryOutcomeDescription": "Ultrasound examination of the prostate performed at the time of biopsy procedures will be include archiving of 3D digital images to allow post-hoc analysis of the images to assess for tissue changes that may be characterized with imaging software.",
                            "SecondaryOutcomeTimeFrame": "prior to performing the biopsy"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To evaluate treatment related tissue changes with ultrasound imaging",
                            "SecondaryOutcomeDescription": "Ultrasound examination of the prostate performed at the time of biopsy procedures will be include archiving of 3D digital images to allow post-hoc analysis of the images to assess for tissue changes that may be characterized with imaging software.",
                            "SecondaryOutcomeTimeFrame": "at the 6-8 month patient office visit"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "A two-step consenting process will be in place for all patients being enrolled to this study. The two-step method is necessary because all patients being enrolled will need to have a repeat transrectal biopsy after meeting the initial study requirements. The two step consent process would enroll patients considering focal cryotherapy into the initial part of the study (QOL assessment at baseline, PCA3 test, and repeat biopsy); those deemed eligible after the re-staging biopsy would be consented to participate in the remainder of the study (focal cryotherapy, QOL studies, repeat biopsy at 6 months for efficacy, PCA3 test).\n\nFirst Step Enrollment\n\nInclusion Criteria:\n\nMen \u2265 21 years of age with a life expectancy estimated to be > 10-years.\nDiagnosis of adenocarcinoma of the prostate and confirmed by MSKCC review\nNo prior treatment for prostate cancer\nECOG performance status of 0 or 1\nProstate cancer clinical stage T1c-T2a\nPSA < 10ng/mL (this will be the PSA level prompting the prostate biopsy)\nProstate Size <60 cc on transrectal ultrasound\nExclusion Criteria:\nMedically unfit for anesthesia\nHistology other than adenocarcinoma\nMen who have received any hormonal manipulation (antiandrogens; LHRH agonists) within the previous 6 months\nMen who are currently receiving anticoagulant drugs (e.g.: Coumadin, warfarin)\n\nSecond Step Enrollment\n\nInclusion Criteria:\n\nRepeat transrectal prostate biopsy that must meet the following parameters:\nMinimum of 12 biopsy cores\nNo Biopsy Gleason grade 4 or 5\nUnilateral cancer (only right-sided or left-sided, not bilateral)\nNo more than 50% cancer in any one biopsy core\nNo more than 25% of cores containing cancer\n\nExclusion Criteria:\n\nMedically unfit for anesthesia\nHistology other than adenocarcinoma\nMen who have received any hormonal manipulation (antiandrogens; LHRH agonists) within the previous 6 months\nMen who are currently receiving anticoagulant drugs (e.g.: coumadin, warfarin)",
                "HealthyVolunteers": "No",
                "Gender": "Male",
                "MinimumAge": "21 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "James Eastham, MD",
                            "OverallOfficialAffiliation": "Memorial Sloan Kettering Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Memorial Sloan-Kettering Cancer Center",
                            "LocationCity": "New York",
                            "LocationState": "New York",
                            "LocationZip": "10065",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "SeeAlsoLinkList": {
                    "SeeAlsoLink": [
                        {
                            "SeeAlsoLinkLabel": "Memorial Sloan-Kettering Cancer Center",
                            "SeeAlsoLinkURL": "http://www.mskcc.org"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000011471",
                            "ConditionMeshTerm": "Prostatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000005834",
                            "ConditionAncestorTerm": "Genital Neoplasms, Male"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005832",
                            "ConditionAncestorTerm": "Genital Diseases, Male"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000011469",
                            "ConditionAncestorTerm": "Prostatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M14025",
                            "ConditionBrowseLeafName": "Prostatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Prostate Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M8636",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8634",
                            "ConditionBrowseLeafName": "Genital Diseases, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14023",
                            "ConditionBrowseLeafName": "Prostatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}